

# **Clinical and experimental studies on theophylline toxicity: in search for and antidote**

**Arunabha Ray**

Department of Pharmacology  
Vallabhbhai Patel Chest Institute  
University of Delhi, Delhi-110 007, India

**Toxicol-2014, Chicago**

# Methylxanthines

- Methylxanthines have been effectively used therapeutically in respiratory disorders, e.g. COPD, asthma, cor pulmonale, apnea in newborns, etc.
- Caffeine (Tea/Coffee) and theophylline (as a drug) commonly used
- Theophylline, a methylxanthine bronchodilator, given for asthma and COPD, and newer uses emerging
- Steroids are the first line of drugs for asthma but are given along with bronchodilators like theophylline to reduce their dosage and reverse steroid resistance
- Theophylline is an effective, pharmacoeconomically viable drug, but has a narrow therapeutic index, i.e. low margin of safety

# Theophylline...

- Toxicity profile includes cardiotoxicity, GI toxicity and CNS toxicity
- Susceptibility to cardiac arrhythmias and seizures is particularly increased in asthmatics in extremes of age
- Cardiac arrhythmias and seizures not preceded by milder warning symptoms and conventional anti consultants are only partially effective against these seizures
- However, in view of its recently demonstrated anti-inflammatory and immunomodulatory effects, it is re-emerging as an important adjunct to therapy in asthma and COPD
- Strategies are being devised to improve the safety profile

# Theophylline.....

- Adenosine antagonism and PDE inhibition are commonly proposed mechanisms of action of theophylline
- CV effects due to increased vascular tone, myocardial contractility, conduction and sympathetic nervous system
- A combination of hemodynamic and neurohumoral effects
- Chronic methylxanthine intake increases CNS and cardiac risk factors
- Mechanisms of such toxicity poorly understood

# PHARMACOVIGILANCE

- The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems
- A tool for drug safety
- Primarily a regulatory issue, but data/concept may to extended to device pharmacological strategies for rational therapy

# ADR monitoring in Asthma and COPD

- 120 patients of bronchial asthma and COPD were selected from the VPCI OPD
- Ethical clearance and GCP guidelines
- Standard inclusion/exclusion criteria
- Diagnosed by clinical features and PFT findings
- ADR profile was recorded as per Pharmacovigilance Programme of India proforma
- Dechallenge and rechallenge were done wherever appropriate
- Causality Assessment was done by using the Naranjo`s scale

## ADR profile with drugs in asthma and COPD

<b>Drugs</b>	<b>Br. Asthma</b>	<b>COPD</b>	<b>Profile</b>
Inhaled steroids	54/60 (90%)	30/60 (50%)	Sore throat, dysphagia, hoarseness, glossitis, others
Inhaled anticholinergics	25/40 (62%)	10/44 (23%)	Dry mouth, thirst, urinary difficulty
Inhaled beta-2 agonists	25/60 (43%)	3/60 (5%)	Hand tremors, palpitations
Oral steroids	28/32 (87%)	3/14 (21%)	Wt. gain, acne, cramps, mood changes
<b>Oral theophylline</b>	14/20 (70%)	20/43 (46%)	Anxiety, dyspepsia, muscle spasm, paresthesia, etc

## **ADR monitoring in OAD...**

- Sex distribution of patients were equal in asthma whereas COPD patients were predominantly males
- All patients received multi-drug treatment schedules (inhalation and oral)
- Most patients received inhaled steroids and bronchodilators
- Few received mucolytics, antibiotics, analgesics, etc.



# Prescription monitoring in obstructive airway disease (theophylline)

<b>Prescriptions</b>	<b>Total No.</b>	<b>With theophylline</b>	<b>%</b>
All patients	120	63	52.6
Br. Asthma	60	20	33.3
COPD	60	43	71.6

## ADR incidence with theophylline

<b>Patients</b>	<b>Received Theophylline</b>	<b>Showed ADRs</b>	<b>%</b>
Br. Asthma	20	14	70
COPD	43	20	46.5
Total	63	34	53.9

## Incidence of ADRs with theophylline in asthma and COPD

<b>ADR</b>	<b>Asthma</b>	<b>COPD</b>
Dyspepsia	45%	65%
<b>Anxiety/Palpitation</b>	<b>50%</b>	<b>60%</b>
Spasm of Muscles	35%	30%
Insomnia	40%	10%
Dizziness	15%	10%
Theophylline Withdrawal Induced Constipation	-	5%
Paraesthesia	20%	10%
Others	10%	5%

## CASUALITY ASSESSMENT OF ADRs DUE TO ORAL THEOPHYLLINE USING THE NARANJO'S SCALE

<b>Drug</b>	<b>Highly Probable (9)</b>	<b>Probable (5-8)</b>	<b>Possible (1-4)</b>	<b>Doubtful (0)</b>
Oral Theophylline	Muscle spasm of calves (most commonly) sternocleidomastoid, intercostal muscles	(1)Dyspepsia (2)Insomnia (3) Anxiety & Palpitation (4)Dizziness (5)Withdrawal induced Constipation (6)Paraesthesia (7)Colicky Pain (8)Diuresis		

# Summary

- Most ADRs were mild to moderate in nature and tolerable
- Few, particularly those related to oral steroids and theophylline, were intolerable and required dose reduction
- Causality assessment showed that most were in the probable category (score from 5 - 8)
- Some effects of oral theophylline and steroids were having scores  $> 9$  (highly probable)
- Such focused studies are helpful in reducing ADRs in OAD and rationalizing drug therapy

# Reverse Pharmacology

- Experimental evaluation/documentation of clinically observed findings
- Reverse pharmacology is an alternative strategy for new drug development
- Reverse pharmacology can play an important role in safety pharmacology studies
- A practice which was successfully employed in the past (eg. Reserpine) and is being more scientifically implemented now

# Reverse pharmacology studies: Basis

- The role of oxidant/anti-oxidant balance in obstructive airway disease has been proposed
- Oxidative stress and drug toxicity connection: adriamycin, paracetamol, etc.
- A connection between theophylline and oxidative stress: OFRs formed during xanthine-XO interactions
- Earlier studies showed that theophylline induced seizures were attenuated by antioxidants
- Preclinical study planned to evaluate the MOA of Theophylline induced ADRs viz. anxiety and tachycardia

# Effects of anti-oxidants on Aminophylline induced Anxiety

---

Treatment (mg/kg)	Elevated Plus Maze (%)	
	OA entry	OA time
Vehicle	30.0 ± 5.6	23.2 ± 3.6
Amino (50)	16.6 ± 4.2*	13.3 ± 2.8*
Amino (100)	9.0 ± 1.3*	5.3 ± 1.1*
TP(40)+Amino(100)	22.2 ± 7.0	15.2 ± 5.0
Mel(50)+ Amino(100)	18.7 ± 6.5 <sup>a</sup>	12.1 ± 4.6 <sup>a</sup>

---

n=8/ group ; TP: tocopherol; Mel: melatonin

\* p< 0.05 (compared to vehicle)

<sup>a</sup>. p<0.05(compared to Amino-50)



## Aminophylline (A) induced anxiety and oxidative stress markers


<b>Treatment (mg/kg)</b>	<b>EPM (%OAE)</b>	<b>Brain MDA nmol/mg pr.</b>	<b>Brain GSH μmol/g tissue</b>
Controls	23.6 ± 3.1	5.2 ± 0.5	9.8 ± 0.3
A (100)	9.0 ± 1.3 *	8.2 ± 1.2 *	6.7 ± 0.8 *
A (50)+ RS	4.0 ± 1.2 *	7.6 ± 0.4 *	4.9 ± 0.4 *
TP + A (100)	17.1 ± 4.4	5.0 ± 0.2	8.0 ± 0.3
Mel + A (100)	22.6 ± 3.8	4.2 ± 0.5	7.6 ± 0.5

## Effects of aminophylline on Mean B.P and Heart rate


Treatment (mg/kg)	Mean B.P(mm Hg)	Heart rate(BPM)
Controls	70.96 ± 2.30	413.79 ± 5.60
Aminophylline (50)	81.00 ± 6.45	402.90 ± 8.52
Aminophylline (100)	80.18 ± 3.33	480.00 ± 6.15 *
Aminophylline (150)	91.66 ± 7.20 *	531.00 ± 16.66 *

# ECG TRACING BY BIOPAC SYSTEM

## CONTROL





## AMINO-50



# ECG TRACING BY BIOPAC SYSTEM

*AMINO (100 mg/kg)*

*AMINO(150mg/kg)*




## Effects of tocopherol on aminophylline induced cardiotoxicity


Treatment(mg/kg)	Mean B.P	Heart rate
Control	70.96 ± 2.30	413.79 ± 5.60
Amino (150)	91.66 ± 7.20	531.00 ± 16.66 *
α-tocopherol (20) + Amino(150)	91.80 ± 6.96	529.40 ± 19.18
α-tocopherol (40) + Amino(150)	72.62 ± 11.49	405.88 ± 29.37 <sup>a</sup>

# Antioxidants and aminophylline toxicity

*$\alpha$ -TP (40 mg/kg) + AMINO (100 mg/kg)*




*$\alpha$ -TP (40 mg/kg) + AMINO (150 mg/kg)*



# Effects of Aminophylline on oxidative stress markers

Group	MDA (nmol /mg protein)	GSH ( $\mu$ mol/mg protein)	SOD (U/mg protein)
Controls	<b>0.35 <math>\pm</math> 0.06</b>	<b>0.57 <math>\pm</math> 0.03</b>	<b>0.51 <math>\pm</math> 0.15</b>
Aminophylline (50 mg/kg)	<b>0.42 <math>\pm</math> 0.10</b>	<b>0.54 <math>\pm</math> 0.09</b>	<b>0.60 <math>\pm</math> 0.21</b>
Aminophylline (100mg/kg)	<b>0.66 <math>\pm</math> 0.08 *</b>	<b>0.44 <math>\pm</math> 0.06</b>	<b>0.44 <math>\pm</math> 0.40</b>
Aminophylline (150mg/kg)	<b>1.02 <math>\pm</math> 0.18 *</b>	<b>0.40 <math>\pm</math> 0.07 *</b>	<b>0.30 <math>\pm</math> 0.02 *</b>

# Effects of $\alpha$ -tocopherol (TP) on aminophylline (A) induced cardiotoxicity





# Summary and Conclusion

- These experimental studies show that theophylline-induced anxiety and tachycardia may be due to oxidative stress, and antioxidants may have protective role
- Thus it could be speculated that treatment with antioxidants may be helpful in preventing such ADRs due to theophylline
- The data of clinical and preclinical studies show that such translational approach could help to highlight some yet unexplored areas of safety pharmacology and toxicology
- The deliverable could be rationalization of drug therapy

# Acknowledgements

- Vallabhbhai Patel Chest Institute
- Department of Science and Technology, Govt of India
- Dr. Kavita Gulati
- Mr. Md. Shamsuzzaman
- Mr. Jagdish Joshi



Thank You